Additionally, the 36-month beta value for ITRM is 2.25. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ITRM is 21.95M and currently, short sellers hold a 0.97% ratio of that float. The average trading volume of ITRM on November 08, 2024 was 2.36M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ITRM) stock’s latest price update
The stock price of Iterum Therapeutics Plc (NASDAQ: ITRM) has surged by 2.69 when compared to previous closing price of 1.30, but the company has seen a 9.43% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2024-10-28 that Iterum Therapeutics plc (NASDAQ:ITRM ) U.S. FDA Approval of ORLYNVAH October 28, 2024 8:30 AM ET Company Participants Louise Barrett – SVP, Legal Affairs & Secretary Corey Fishman – President, Director & CEO Steven Aronin – SVP & Head, Clinical Development Conference Call Participants Operator Hello, everyone, and welcome to Iterum Therapeutics call to discuss the recent approval of ORLYNVAH the treatment of Uncomplicated UTIs. My name is Lydia, and I’ll be your operator today.
ITRM’s Market Performance
ITRM’s stock has risen by 9.43% in the past week, with a monthly rise of 43.56% and a quarterly rise of 13.14%. The volatility ratio for the week is 9.38% while the volatility levels for the last 30 days are 15.89% for Iterum Therapeutics Plc The simple moving average for the past 20 days is 7.86% for ITRM’s stock, with a -0.16% simple moving average for the past 200 days.
Analysts’ Opinion of ITRM
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ITRM reach a price target of $2.50. The rating they have provided for ITRM stocks is “Buy” according to the report published on March 15th, 2021.
RBC Capital Mkts gave a rating of “Sector Perform” to ITRM, setting the target price at $2 in the report published on June 02nd of the previous year.
ITRM Trading at 18.57% from the 50-Day Moving Average
After a stumble in the market that brought ITRM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.60% of loss for the given period.
Volatility was left at 15.89%, however, over the last 30 days, the volatility rate increased by 9.38%, as shares surge +44.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +21.82% upper at present.
During the last 5 trading sessions, ITRM rose by +9.84%, which changed the moving average for the period of 200-days by -32.32% in comparison to the 20-day moving average, which settled at $1.2380. In addition, Iterum Therapeutics Plc saw -32.23% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ITRM starting from Dunne Michael W., who purchase 25,000 shares at the price of $1.40 back on Dec 22 ’23. After this action, Dunne Michael W. now owns 113,754 shares of Iterum Therapeutics Plc, valued at $35,000 using the latest closing price.
Dunne Michael W., the Director of Iterum Therapeutics Plc, purchase 10,000 shares at $1.84 during a trade that took place back on Dec 18 ’23, which means that Dunne Michael W. is holding 88,754 shares at $18,442 based on the most recent closing price.
Stock Fundamentals for ITRM
Current profitability levels for the company are sitting at:
- -14.6 for the present operating margin
- 0.66 for the gross margin
The net margin for Iterum Therapeutics Plc stands at -10.82. The total capital return value is set at 14.71. Equity return is now at value -555.68, with -86.93 for asset returns.
Based on Iterum Therapeutics Plc (ITRM), the company’s capital structure generated 2.02 points at debt to capital in total, while cash flow to debt ratio is standing at -1.92. The debt to equity ratio resting at -1.98. The interest coverage ratio of the stock is -21.7.
Currently, EBITDA for the company is -45.72 million with net debt to EBITDA at -0.45. When we switch over and look at the enterprise to sales, we see a ratio of 17.92. The receivables turnover for the company is 13.44for trailing twelve months and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.77.
Conclusion
In conclusion, Iterum Therapeutics Plc (ITRM) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
